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Abstract 
 
Sphingolipids are key components of eukaryotic membranes, particularly the plasma 
membrane. The biosynthetic pathway for the formation of these lipid species is largely 
conserved. However, in contrast to mammals, which produce sphingomyelin, organisms 
such as the pathogenic fungi and protozoa synthesize inositol phosphorylceramide (IPC) 
as the primary phosphosphingolipid. The key step involves the reaction of ceramide and 
phosphatidylinositol catalysed by IPC synthase, an essential enzyme with no mammalian 
equivalent encoded by the AUR1 gene in yeast and recently identified functional 
orthologues in the pathogenic kinetoplastid protozoa. As such this enzyme represents a 
promising target for novel anti-fungal and anti-protozoal drugs. Given the paucity of 
effective treatments for kinetoplastid diseases such as leishmaniasis, there is a need to 
characterize the protozoan enzyme. To this end a fluorescent-based cell-free assay 
protocol in a 96-well plate format has been established for the Leishmania major IPC 
synthase. Using this system the kinetic parameters of the enzyme have been determined 
as obeying the double displacement model with apparent Vmax = 2.31 pmol.min−1.U−1. 
Furthermore, inhibitory substrate analogues have been identified. Importantly this assay is 
amenable to development for use in high-throughput screening applications for lead 
inhibitors and as such may prove to be a pivotal tool in drug discovery.  
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1. Introduction 
 
The insect vector borne protozoan parasites of the family Kinetoplastidae cause a range of 
human diseases, including the leishmaniases and African Sleeping Sickness. These 
infections are of increasing prevalence, particularly in developing countries, and have 
been classified by the World Health Organisation as Category I emerging or uncontrolled 
diseases (Remme, et al. 2002). For example, the Leishmania spp. (the causative agents of 
the leishmaniases) infect more than 12 million people in five continents and are endemic in 
88 nation states putting over 350 million people at risk, with instances of leishmaniasis not 
uncommon in certain regions of North America and southern Europe. Moreover, the 
spread and severity of disease is exacerbated by its status as an important co-infection in 
AIDS patients and the overlap in prevalence of HIV and Leishmania (Alvar, et al. 2008). In 
the absence of effective vaccines, the treatment of kinetoplastid infections is difficult with 
the most serious visceral form of leishmaniasis often requiring a long, costly course of drug 
therapy. In addition, available drugs often exhibit serious side-effects and resistance is 
rapidly emerging (Remme, et al. 2002). These facts make the discovery and validation of 
new therapeutic agents a priority. 
The diverse, amphipathic sphingolipids consist of a sphingoside backbone with long-chain 
base and polar alcohol attachments. These essential lipid species are found in all 
eukaryotic cells, as well as in some prokaryotic organisms and viruses (Smith and Merrill 
2002). In eukaryotes, the unmodified sphingolipid, ceramide, is a precursor for the 
synthesis of complex sphingolipids in the Golgi apparatus. The resultant lipid species are 
subsequently concentrated in the outer leaflet of the plasma membrane. Here, together 
with sterols, they form the microdomains known as lipid rafts (Futerman and Hannun 
2004). Such domains have been suggested to be central to a wide array of cellular 
processes, including the formation of signal transduction complexes (Magee, et al. 2002; 
Pierce 2002) and the polarized trafficking of lipid-modified proteins (Brown and London 
1998). Importantly, sphingolipid metabolites such as ceramide and phosphorylated 
sphingosine (sphingosine-1-phosphate), are also involved in the intracellular signal 
transduction processes that regulate cell growth, differentiation and programmed cell 
death (apoptosis) (Futerman and Hannun 2004). 
Sphingolipids demonstrate structural divergence in evolution. Whilst sphingomyelin (SM) is 
the predominant phosphosphingolipid (PSL) of mammalian cells, inositol 
phosphorylceramide (IPC) is found in the fungi, plants and some protozoa but not in 
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mammals (Lester and Dickson 1993; Sperling and Heinz 2003). SM is formed by the 
transfer of the phosphorylcholine head group from the phospholipid phosphatidylcholine 
(PC) to ceramide, a reaction catalyzed by SM synthase (Huitema, et al. 2004). The related 
enzyme, IPC synthase, mediates the formation of IPC in fungi, plants and the pathogenic 
kinetoplastid protozoa (e.g. Leishmania spp.) by catalyzing the transfer of 
phosphorylinositol from phosphatidylinositol (PI) to ceramide or phytoceramide (Becker 
and Lester 1980; Bromley, et al. 2003; Denny, et al. 2006). In the fungi this enzyme activity 
has been attributed to the AUR1p protein first identified in Saccharomyces cerevisiae and 
subsequently in several fungal pathogens (Heidler and Radding 1995; Heidler and 
Radding 2000). We have isolated a functional orthologue of this protein in the 
kinetoplastid, protozoan parasite Leishmania major (LmjIPCS) (Denny, et al. 2006). 
LmjIPCS is encoded by a single gene (GeneDB, LmjF35.4990), and closely related 
orthologues are found in the complete genome sequences of the related kinetoplastid 
pathogens, Trypanosoma brucei (the causative agent of African Sleeping Sickness) and T. 
cruzi (Chagas Disease) (Denny, et al. 2006). IPC synthase activity is evident in both the 
insect and mammalian stages of the L. major lifecycle, however in the intra-macrophage 
form the parasite is predicted to scavenge host cell ceramide for use as substrate by 
LmjIPCS (Zhang, et al. 2005; Zhang, et al. 2009). 
As an essential activity with no mammalian equivalent the fungal IPC synthase has 
become a recognized and well studied drug target (Georgopapadakou 2000; Nagiec, et al. 
1997). The discovery of functional orthologues in the kinetoplastid pathogenic protozoa 
has led to its further consideration as an anti-protozoal target (Suzuki, et al. 2008). It is 
known that LmjIPCS activity is susceptible to the established fungal inhibitor aureobasidin 
A (Denny, et al. 2006). In addition, this compound has been demonstrated to inhibit the 
growth and infectivity of L. amazonensis (Tanaka, et al. 2007). Furthermore, recent work in 
our laboratory (Mina, et al. 2009) and elsewhere (Sutterwala, et al. 2008) has both 
genetically and pharmacologically validated the kinetoplastid enzyme as a target in T. 
brucei. Therefore, further study of the LmjIPCS (and other kinetoplastid orthologues) is 
vital in moving towards the ultimate goal of identifying compounds with the potential for 
development into much needed, pharmacologically active anti-protozoals. Herein we 
report the establishment of a robust 96-well plate based assay system that uses easily 
obtainable, transgenic yeast-derived material, together with its application to detail the 
kinetic parameters of LmjIPCS and demonstrate the inhibitory effects of several substrate 
analogues.  
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2. Materials and Methods 
 
2.1. Materials 
Phosphatidylinositol (bovine liver PI; predominant species 1-stearoyl-2-arachidonoyl-sn-
glycero-3-phospho-1'-myo-inositol sodium salt) was from Avanti Polar Lipids. D-erythro-
sphingosine (d18:1; sphing-4-enine, (2S,3R,E)-2-aminooctadec-4-ene-1,3-diol) and N-
acetyl-D-erythro sphingosine (d18:1/2:0; N-acetyl-sphing-4-enine, (2S,3R,4E)-N-acetyl-2-
aminooctadec-4-ene-1,3-diol) were from TOCRIS BioScience. C18-Ceramide (d18:1/18:0; 
N-stearoyl-D-erythro-sphingosine, (2S,3R,4E) N-stearoyl-2-aminooctadec-4-ene-1,3-diol) 
and diacylglycerol (1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol) were 
from Sigma Aldrich. NBD-C6-ceramide (N-[6-[(7-nitro-2-1,3-benzoxadiazol-4-
yl)amino]hexanoyl]-D-erythro-sphingosine) was from Invitrogen. 
 
2.2. Preparation of LmjIPCS microsomal material 
Auxotrophic AUR1 mutant Saccharomyces cerevisiae was complemented by the 
expression of the L. major IPC synthase to create YPH499–HIS–GAL–AUR1 pRS246 
LmjIPCS (Denny, et al. 2006). These cells were propagated in SD medium (0.17% Bacto 
yeast nitrogen base, 0.5% ammonium sulphate and 2% dextrose) containing the 
appropriate nutritional supplements, and microsomes prepared from an exponentially 
growing culture (Fischl et al., 2000). Briefly, approximately 8.0 g of wet cell mass was 
suspended in STE buffer (25 mM Tris HCl pH 7.4, 250 mM sucrose and 1 mM EDTA) 
containing Complete® EDTA-free Protease Inhibitor Cocktail (Roche Applied Science) and 
the yeast disrupted by vortex mixing with pre-chilled acid-washed glass beads (425-600 
µm, Sigma Aldrich). After the removal of the glass beads, unbroken cells and cell-wall 
debris by centrifugation (1500g, 4°C and 15 minutes), the microsomal membrane fraction 
was isolated by differential centrifugation. Subsequently the large granular fraction was 
removed (27000 g, 4 °C and 30 minutes) and the microsomal membrane fraction isolated 
(150000 g, 4 °C and 90 minutes). The microsomes were re-suspended at a concentration 
of 10 mg.ml-1 in storage buffer (50 mM Tris/HCl pH 7.4, 20% (v/v) glycerol, 5 mM MgCl2) 
containing protease inhibitor. As required, the microsomal membranes were washed in 
2.5% CHAPS (Sigma Aldrich; 4 °C, 60 minutes), isolated by centrifugation (150000 g, 4°C 
and 90 minutes), assayed for protein content (CBQCA, Invitrogen) and re-suspended in 
storage buffer. A second wash inactivated the enzyme. 
Different preparations of microsomal membranes were utilized in this study and these 
varied in specific LmjIPCS enzyme activity. Therefore, to standardise the assay material 
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samples were normalized with respect to active enzyme content ensuring consistency 
across experiments. Although the standardised unit for enzymatic activity is the katal 
where 1 kat = 1 mol(product).s−1 (International Union of Biochemistry, 1979), for the range 
of substrates concentrations used in the work presented here a more practical value is 
enzyme unit (U). One unit (U) of enzyme is defined as that which converts 1 pmol of 
substrate per minute under the conditions described (1 U = 1 pmol(product).min−1), where 
1 U corresponds to 16.67 femtokats (Fischl et al., 2000). The conversion of the fluorescent 
acceptor substrate NBD-C6-ceramide to the product NBD-C6-IPC was measured and 
quantified with respect to known concentrations of NBD-C6-ceramide, activity calculated as 
U.µl-1 and the samples were stored at -80 °C until use. Enzyme turnover was calculated 
per milligrams of total protein in the sample (U.mg-1). 
 
2.3. Thin layer chromatography (TLC) based LmjIPCS synthase assay 
Both unwashed and CHAPS-washed (1 µg) microsomal membranes were used in a 50 µl 
assay mix containing 1 mM PI, 100 mM Tris HCl (pH7.4) and 200 µM NBD-C6-ceramide 
(Figueiredo et al., 2005). The reaction was pre-incubated before the addition of the NBD-
C6-ceramide at 30 °C (the established optimum temperature in the assay) for 30 minutes 
and subsequently for a further hour before quenching with 150 µl of 
chloroform:methanol:water (10:10:3). After biphasic separation the organic layer was 
removed, dried in a rotavapor (Eppendorf Concentrator 5301) and re-suspended in 20 µl of 
10:10:3. The reaction products were fractionated using HPTLC silica plates (Merck) and 
the eluent system chloroform:methanol:aqueous 0.25% KCl (55:45:10). The Rf values for 
the substrate, NBD-C6-ceramide, and the product, NBD-C6-IPC were 0.96 and 0.57 
respectively. Quantification was carried out using a FLA3000 scanner (Fujifilm) and AIDA 
Image Analyzer® software (version 3.52). 
  
2.4. 96-well plate-based LmjIPCS synthase assay for kinetic analyses 
CHAPS-washed membranes (Aeed, et al. 2004), 0.6 U or as described, were used in a 
reaction mix containing 100 µM (or as indicated) PI, 50 mM KH2PO4 (pH7.0) and 5 µM (or 
as indicated) NBD-C6-ceramide. Following pre-incubation at 30°C for 30 minutes, the 
reaction was initiated by the addition of the NBD-C6-ceramide (5 µM or as indicated) and 
2.4 mM CHAPS. The reaction was incubated for the specified period of time and 
subsequently quenched by the addition of 200 µl of methanol. Separation of the reaction 
product, NBD-C6-IPC, from the substrate NBD-C6-ceramide was achieved by applying the 
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reaction mix to 100 µl (sedimented gel volume) of AG4-X4 resin (BioRad), formate form, in 
96-well Multiscreen Solvinert filter plates (Millipore) using a vacuum manifold (Millipore). 
The resin was washed 5 times with 200 µl methanol, the product was eluted into 
OptiPlate 96-F plates (Perkin Elmer) using 200 µl of 1 M potassium formate in methanol 
and quantified using a fluorescence plate reader (FLx800™, BioTek) - excitation λ = 485 
nm; emission λ = 528 nm. Assays used were carried out in triplicate and results analysed 
using Prism 5.0 software (GraphPad) and Excel® Solver Add-in (Microsoft Office). The 
separation protocol was validated by collecting fractions from a 5-fold scale up of the 
process and fractionating them by TLC as above (figure 1). 
Substrate analogues were employed in inhibition studies and added with the fluorescent 
substrate NBD-C6-ceramide in the quantities indicated. 
The assay system was validated as excellent for screening purposes with a Z’ value of 
0.58  (Zhang, et al. 1999). Calculation of this value utilized 2 bespoke inhibitors, (4E) N-
(phenylacetyl)-1-deoxy-sphing-4-enine and (2R,4E) N-phenylacetyl2-aminooctadec-4-en-
1-ol whose synthesis and screening will be subsequently reported. 
 
2.5. Mass spectrometry 
Analyses were performed on an LTQFT (ThermoFinnigan Corp); an FTICR MS instrument 
equipped with a 7.0 T magnet.  Chloroform extracts were introduced into the electrospray 
ion source by direct infusion from a syringe at a flow rate of 3 µl.min-1.  Positive ion 
measurements were made with the source voltage at 4.0 kV and negative ion 
measurements were made with the source voltage at 3.5 kV. The tube lens was kept at 
100 V and the source temperature at 275 °C for all experiments. 
 
2.6. Cytotoxicity screening 
L. major (MHOM/IL/81/Friedlin)  and L. mexicana (MNYC/BZ/62/M379)  parasites were 
maintained at 26 °C in Schneider’s Drosophila media (Sigma Aldrich) supplemented with 
heat inactivated foetal bovine sera (15% for promastigotes and 20% for amastigotes; 
Biosera). L. mexicana promastigotes were transformed into axenic amastigotes by a pH 
and temperature shift as previously described (Bates, 1994). In 96-well plates (Nunc) 
parasites at 105ml-1 were incubated with compounds in triplicate (including miltefosine 
(Cayman Chemical) as a positive control, and untreated parasites and media as negative 
controls) for 24 hours before incubation with Alamar Blue (Invitrogen) for 4 hours prior to 
assessing cell viability using a fluorescent plate reader (Biotek; 560EX nm/600EM nm). 
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LD50 was calculated after plotting cell viability (as % of untreated control) against log 
compound concentration (µM). 
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3. Results and Discussion  
 
3.1. Assay of LmjIPCS microsomal material 
The high levels of endogenous PI present in yeast microsomes (Aeed, et al. 2004) 
rendered establishing the kinetic parameters of LmjIPCS with respect to this donor 
substrate problematic. Initial assay experiments using unrefined material derived from 
LmjIPCS complemented HIS-GAL-AUR1 auxotrophic yeast IPCS mutants (Denny, et al. 
2006) demonstrated that endogenous, microsomal PI accounted for approximately 25% of 
the measured LmjIPCS turnover (figure 2A), making accurate determination of the enzyme 
kinetic parameters impossible. A similar problem has previously been identified with the 
use of Trypanosoma cruzi derived microsomes in an assay of TcIPCS turnover 
(Figueiredo, et al. 2005 ). However, it has been demonstrated that washing microsomal 
membranes derived from the pathogenic yeast, Candida albicans with a zwitterionic 
detergent (CHAPS) removed endogenous substrate lipids without affecting IPCS activity 
(Aeed, et al. 2004). Adopting this approach and employing microsomes from LmjIPCS 
complemented HIS-GAL-AUR1 yeast, washed with CHAPS as described, the parasite 
enzyme assay proved to be dependent not only on the addition of the fluorescent acceptor 
substrate, NBD-C6-ceramide, but now also more than 90% dependent on the addition of 
the donor substrate (bovine liver PI; figure 2A). It has previously been demonstrated that 
the S. cerevisiae orthologous enzyme, AUR1p, is unable to utilise bovine liver PI (Mina, et 
al. 2009). In the present assay system, the CHAPS-washed microsomes also 
demonstrated an approximately 2-fold higher level of enzyme turnover than equivalent 
quantities of crude material (figure 2B). This increase is most likely due to enrichment of 
the sample for LmjIPCS as other proteins are washed away from the detergent insoluble 
material. However, the removal of microsomal proteins and lipids may also reduce the 
spatial volume of the washed material leading to more rapid diffusion of applied 
exogenous substrates into the membranes. Taken together these data indicate that 
washing the microsomes with CHAPS depletes them of PI, and perhaps (phyto)ceramide, 
thereby facilitating more accurate determination of the kinetics of LmjIPCS. Moreover, the 
fact that LmjIPCS remained highly active within a detergent resistant lipid environment 
suggests that the enzyme may reside within CHAPS-resistant lipid microdomains in vivo 
(Rouvinski, et al. 2003). 
 
 10 
3.2. Determination of LmjIPCS assay parameters 
Using the 96-well plate formatted system described, reproducible, quantitative kinetic data 
could be obtained for the enzyme from CHAPS-washed LmjIPCS yeast microsomes. In 
the first instance the formation of product (IPC) over time was determined. The results 
demonstrated that the reaction rate is linear for 30 minutes before it decreases over time 
(figure 3A). As a consequence all subsequent assays were performed with a 15 minute 
reaction time to ensure linearity under the specified conditions, turnover was assumed to 
be equivalent to initial velocity (v0).  
Since both substrates are in excess and only approximately 12 % of the limiting acceptor 
substrate, NBD-C6-ceramide, is consumed after 1 hour, the reasons for the decrease in 
reaction rate above 30 minutes are unclear. The IPC product may be localised around the 
enzyme affecting a change in the diffusion rate of the substrates to the active site. It is also 
possible that LmjIPCS activity is modulated by inhibitory feedback from the synthesized 
NBD-C6-IPC or diacylglycerol (DAG) which is formed as a by-product of IPC synthase 
turnover (Denny, et al. 2006).  Analysis of the inhibitory affect of DAG indicated a logIC50 
value of 0.92±0.8 and an IC50 of 8.3 µM (figure 3B) supporting the latter hypothesis. 
Product (NBD-C6-IPC) formation also increased in a linear manner with increasing enzyme 
concentration up to 0.8 U/assay (figure 3C). However, the linear relationship deviated 
beyond this point (data not shown). Notably, increasing the concentration of enzyme also 
leads to a change in the protein : lipid : detergent (CHAPS) ratio and hence modulates the 
substrate concentration at the active site of LmIPCS. Taking this observation into account 
0.6 U of LmIPCS (within the linear range) was employed in all subsequent analyses.  
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3.3 Determination of LmjIPCS kinetic parameters 
Having established a standardized set of conditions that gave a linear response, and in 
which endogenous interfering substrate was minimized by detergent washing, the kinetic 
parameters of LmjIPCS with respect to both the acceptor (NBD-C6-ceramide) and donor 
(PI) substrates were determined. Initially, the data obtained were tested against the 
Michaelis-Menten model and with respect to increasing concentrations of NBD-C6-
ceramide gave a curve of good fit (R2 = 0.97; figure 4A). The apparent Km for the acceptor 
substrate was 3.5±0.35 µM and the apparent Vmax 2.1±0.07 pmol.min−1.U−1. However, 
determination of the Hill constant revealed a Hill slope of 2.7 that indicated co-operative 
binding of substrates was occurring (Hill 1910). 
In contrast, with [NBD-C6-ceramide] fixed at 5 µM, the data with respect to the PI showed 
a poor fit to the Michaelis-Menten equation (R2 = 0.82; figure 4B), with considerable 
deviation at high concentrations of donor substrate. The enzyme orthologue from the 
pathogenic yeast C. albicans has previously been shown to behave in a similar manner, a 
phenomenon which was described as being caused by substrate inhibition (Aeed, et al. 
2004). However, at a higher, saturating concentration of the acceptor substrate, [NBD-C6-
ceramide] = 20 µM (> 5x apparent Km), no apparent inhibition at high [PI] could be 
detected (figure 4C). This strongly suggested that activity is dependent on the substrate 
molar ratio, with a dilution effect being observed with low NBD-C6-ceramide (5 µM) and 
high PI (>150 µM). The % molar concentration of NBD-C6-ceramide dropped 30% from 
0.82% at 12.5 µM PI and 600 µM CHAPS to 0.58% 250 µM PI and 600 µM CHAPS. In 
contrast a change in concentration of the acceptor substrate has little affect on the % 
molar concentration of PI (14.3% at 1 µM NBD-C6-ceramide and 600 µM CHAPS to 13.9% 
20 µM NBD-C6-ceramide NBD-C6-ceramide and 600 µM CHAPS) and CHAPS 
concentration. 
PI vesicles can be solubilised by CHAPS far below the CMC of this detergent at 0.27 mM 
([Dw]c : critical concentration of free detergent; Schürholz 1996). Therefore under the 
experimental conditions employed (0.6mM CHAPS) in the assay system PI/CHAPS mixed 
micelles are formed. The molar detergent to lipid ration of these micelles (Rc) is 0.17, 
meaning that CHAPS is a minor component, approximately 15% of the total molar 
concentration in micelles (Schürholz 1996). Based on these data the [Dw]c in the assay 
system employed can be calculated using Equation 1 (Schürholz 1996). 
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Equation 1 
At [DT]c= 600 µM in the reaction mix the [Dw]c (270µM) is exceeded under all conditions 
employed in this study and CHAPS exists primarily in a monomeric form with a minor 
proportion associated with PI in micelles (2.8% at 100µM PI).  
Given the fact in this complex system the LmjIPCS is a membrane enzyme acting on lipid 
substrates within mixed micelles the deviation from Michaelis-Mention kinetics observed is 
unsurprising. To facilitate further analyses a number of assumptions were made, namely: 
the kinetic parameters would be determined using the steady state approach; initial rate 
assumptions are applied; PI/CHAPS micelles have a low molar % of CHAPS 
(approximately 15%); all lipids and detergent molecules have the same surface area; all 
lipids and detergent molecules have equal accessibility to the enzyme active site. All 
concentrations are expressed as molar fractions of total lipid plus detergent 
Subsequently a series of assay reactions were carried out with varying acceptor substrate 
concentrations, [NBD-C6-ceramide], at different fixed [PI] (12.5 − 100 µM). A global 
analysis of the data points (56 mean points of 168 replicates) employing the surface 
dilution kinetic model, which considers the surface concentration of lipids ([PI] and [Cer] 
expressed as mol% in PI/CHAPS micelles; Deems, et al. 1975), resulted in non-
convergent results. However, given that LmjIPCS is an integral membrane protein within 
microsomal membranes the enzyme can fuse with PI/CHAPS micelles, or maintain its 
integrity and bounce between micelles whilst interacting with the bulk monomeric 
CHAPS/NBD-C6-ceramide in the assay buffer. Both cases would confer bulk concentration 
dependence to the kinetics (Carman, et al. 1995).  
Lineweaver-Burk analyses of the data set gave a near parallel pattern (figure 5A), with a 
plot of the intercepts demonstrating a linear correlation to 1 / [PI] molar % (figure 5B). A 
subsequent global analysis of these data in terms of a generalised form of a bi-bi substrate 
kinetic equation (Engel 1977; Equation 2) provided a solution for the values of the 
equation parameters, where Ø0 = 0.26, ØA = 0.82, ØB = 0.14, ØAB = 1.0 × 10−5. From these 
Vmax  = 2.31 pmol.min-1.min-1, Km [PI] = 3.15 molar % and Km [NBD-C6-ceramide] = 0.54 
molar %.  
 13 
 
 
Equation 2 
Notably, the relatively high affinity of the acceptor substrate for LmjIPCS compared with 
that of the donor PI was consistent with the proposal that ceramide, a highly bioactive 
molecule, is the rate-limiting substrate in the in situ IPC synthase reaction. In contrast PI is 
a relatively abundant substrate in most membraneous environments (Aeed, et al. 2004; 
Dickson 1998; Leber, et al. 1995). 
Based on these data the value ØAB was assumed to be zero thereby reducing Equation 2 
to that describing double displacement kinetics (Equation 3). Details of the factors of Ø0, 
ØA , ØB is detailed in supplementary data (S1). 
 
 
Equation 3 
These analyses provide strong support for the notion that LmjIPCS functions via a double 
displacement model. This is further evidenced by the close correlation of experimental 
data with simulations derived from Equation 3 (figure 5C and D). 
With this in mind, the apparent fit to the Michaelis-Menton model with respect to ceramide 
initially observed was most likely due to pre-incubation with saturating levels of PI leaving 
the majority of the enzyme in an intermediate phosphorylated state. In this state it is 
predicted that LmjIPCS has mediated the transfer of the phosphorylinositol group of PI to 
the reactive histidine within the identified catalytic triad (Denny, et al. 2006) with the 
concomitant release of DAG. Notably mutation of His-294 within the yeast AUR1p triad 
has been shown to result in non-viable haploid cells (Levine, et al. 2000) and the 
equivalent mutation (His-264) in LmjIPCS rendered it unable to complement auxotrophic 
AUR1p mutant yeast (Mina and Denny, unpublished). The second step in the reaction is 
then initiated by the addition of acceptor substrate (ceramide) when the phosphorylated 
intermediate is subjected to nucleophilic attack by the oxygen of the ceramide hydroxyl 
group, resulting in phosphoryl group transfer to the sphingoid base thus forming IPC.  
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3.4. Substrate analogues as competitive inhibitors 
The delineation of the kinetic parameters of LmjIPCS also provided the opportunity to 
begin to further understand the mode of action of this enzyme and perhaps, via a rational 
approach, to design specific inhibitors. Given the high affinity of the acceptor substrate for 
LmjIPCS, the ability of natural ceramide (Cer; 18:1/18:0; N-stearoyl-D-erythro-sphingosine) 
and the ceramide analogues D-erythro-sphingosine and N-acetyl-D-erythro-sphingosine to 
compete with fluorescent NBD-C6-ceramide was analyzed, with variation in the quantity of 
the product (NBD-C6-IPC) reflecting the effect of the substrate competitors on enzyme 
turnover. 
Unlike N-acetyl-D-erythro-sphingosine and D-erythro-sphingosine, N-stearoyl-D-erythro-
sphingosine was insufficiently soluble in the phosphate-based buffer employed for the 
microtitre plate assay, curtailing analysis. This problem could be circumvented by using a 
Tris-based buffer system containing defatted-BSA. Here N-stearoyl-D-erythro-sphingosine 
was soluble and the results indicated that NBD-C6-ceramide exhibited an affinity for 
LmjIPCS equivalent to that of the natural substrate (data not shown). Analyses of the more 
soluble synthetic analogues, N-acetyl-D-erythro-sphingosine and D-erythro-sphingosine, 
using the phosphate-based buffer system in the 96-well plate based assay demonstrated 
that they are, as expected, competitive with respect to NBD-C6-ceramide: IC50 values of 16 
µM and 52 µM respectively (figure 6A and B). Subsequent MS-ES+/ES− analyses of the 
reaction product profiles (figure 7) revealed the presence of a mass of 582.3 
corresponding to IP-N-acetyl-D-erythro-sphingosine confirming that N-acetyl-D-erythro-
sphingosine had been turned over by LmjIPCS. This was expected as this ceramide 
analogue has previously been shown to act as a substrate for the yeast enzyme (Nagiec, 
et al. 1997). Conversely, no IP-D-erythro-sphingosine could be detected in the MS spectra 
either in positive or negative ion mode, which indicated that D-erythro-sphingosine is not a 
substrate for LmjIPCS, rather it is acting as a true inhibitor (data not shown). Screening 
this inhibitor against L. major and L. mexicana promastigotes (insect stage) and L. 
mexicana amastigotes (mammalian stage) demonstrated its efficacy against both species 
and lifecycle stages (LD50 of 6.5µM, 8.2 µM and 13.3µM respectively; table 1). It should be 
noted that it is unclear whether this was a target specific effect, however the substrate 
analogue N-acetyl-sphingosine was considerably less cytotoxic such that it was not 
possible to determine its LD50 versus L. mexicana amastigotes (table 1). 
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In structure-function terms these data indicated that the free-amino group present in D-
erythro-sphingosine abolishes enzyme activity, whilst masking this group with even a 
minimal acyl moiety (N-acetyl-D-erythro-sphingosine) restored it. Similarly, sphingosine 
analogues have demonstrated an inhibitory effort on the S. cerevisiae phosphatidate 
phosphatase (Wu, et al. 1993), a member of the LPP enzyme superfamily which are 
believed to share a mechanism of action with the sphingolipid synthases (Huitema, et al. 
2004). Taken together it may be hypothesized that the protonated free-amino group of D-
erythro-sphingosine electrostatically interferes with the active site of these enzymes, an 
observation which may potentially be exploited in the rational design of specific enzyme 
inhibitors. 
 
4. Summary 
 
Using the multi-well format assay established in this work we have deduced the kinetic 
parameters of LmjIPCS with respect to both the donor (PI) and acceptor (NBD-C6-
ceramide) substrates, and provided evidence that the enzyme functions through a bi-bi 
(ping-pong) substrate kinetic model. These data provide the first direct indication of the 
mechanism of action of the sphingolipid synthase family. Such analyses would not have 
been possible using a conventional assay system such as that previously employed for the 
T. cruzi orthologue (Figueiredo, et al. 2005). However, by employing a complemented 
yeast system, large quantities of active LmjIPCS could be isolated in a cost effective 
manner avoiding the handling of pathogenic material. Furthermore washing the 
microsomal starting material with CHAPS removed endogenous, contaminating donor 
substrate (PI) leaving an environment in which the enzyme exhibited not only a 
dependency on exogenous PI, but also a higher level of specific activity.  
With a Z’ value of 0.58 (Zhang, et al. 1999), the assay system described lends itself to 
high-throughput screening for inhibitors of a protozoal enzyme activity that has been 
demonstrated to be essential for kinetoplastid pathogens (Mina, et al. 2009; Sutterwala, et 
al. 2008). The assay of ceramide analogues demonstrated this potential and provides the 
backbone for consideration of rationally designed enzyme inhibitors. In the longer term, it 
is hoped that it will assist in the discovery of new, much needed therapies for 
leishmaniasis and African sleeping sickness. 
 
 16 
Acknowledgements 
 
This work was funded by Biotechnology and Biological Research Council (BB/D52396X/1) 
and Royal Society (2005/R1) grants to PWD and a British Council/Deutscher 
Akademischer Austausch Dienst Academic Research Collaboration Award to PWD and 
RTS. JGM is funded by an Overseas Research Studentship and a Wolfson Research 
Institute Award. JAM is an Engineering and Physical Sciences Research Council 
Academic Fellow. This work was also supported in part by Deutsche 
Forschungsgemeinschaft, Bonn and a Wolfson Research Institute Small Grants Award. 
We thank Drs Ann-Marie O'Donoghue and David Hodgson (Department of Chemistry, 
Durham University) and Dr Buddhapriya Chakrabarti (Department of Mathematical 
Sciences, Durham University) for helpful discussion. 
 17 
References 
 
Aeed PA, Sperry AE, Young CL, Nagiec MM, Elhammer ÅP. Effect of membrane 
perturbants on the activity and phase distribution of inositol phosphorylceramide synthase, 
development of a novel assay. Biochemistry 2004;43:8483 - 93 
Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, Gradoni L, Ter Horst R, 
López-Vélez R, Moreno J. The relationship between leishmaniasis and AIDS: the second 
10 years. Clin Microbiol Rev 2008;21:334 -359 
Bates, PA. Complete developmental cycle of Leishmania mexicana in axenic culture. 
Parasitol 1994;108: 1-9 
Becker GW, Lester RL. Biosynthesis of phosphoinositol-containing sphingolipids from 
phosphatidylinositol by a membrane preparation from Saccharomyces cerevisiae. J 
Bacteriol 1980;142:747  - 54 
Bromley PE, Li YO, Murphy SM, Sumner CM, Lynch DV. Complex sphingolipid synthesis 
in plants: characterization of inositolphosphorylceramide synthase activity in bean 
microsomes. Arch Biochem Biophys 2003;417:219 - 26 
Brown DA, London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev 
Biol 1998;14:111 - 36 
Carman GM, Deems RA, Dennis EA. Lipid signaling enzymes and surface dilution kinetics. 
J Biol Chem 1995;270:18711 - 14 
Demms RA, Eaton BR, Dennis EA. Kinetic anlaysis of phospholipase A-2 activity toward 
mixed micelles and its implications for the study of liplytic enzymes. J Biol Chem 
1975;250:9013 - 20 
Denny PW, Shams-Eldin H, Price HP, Smith DF, Schwarz RT. The protozoan inositol 
phosphorylceramide synthase: a novel drug target which defines a new class of 
sphingolipid synthase J Biol Chem 2006;281:28200-  09 
Dickson RC. Sphingolipid functions in Saccharomyces cerevisiae: comparision to 
mammals. Annu Rev Biochem 1998;67:27 - 48 
Engel CP. Enzyme kinetics: The steady-state approach 1 st ed. John Wiley & Sons; 1977 
Figueiredo JM, Dias WB, Mendonca-Previato L, Previato J, Heise N. Characterization of 
the inositol phosphorylceramide synthase activity from Trypanosoma cruzi. Biochem J 
2005;387:519 - 29 
Fischl AS, Liu Y, Browdy A, Cremesti AE. Inositolphosphorylceramide synthase from 
yeast. Methods Enzymol 2000;311:123 - 130 
Futerman AH, Hannun YA. The complex life of simple sphingolipids. EMBO Reports 
2004;5:777 - 82 
 18 
Georgopapadakou NH. Antifungals targeted to sphingolipid synthesis: focus on inositol 
phosphorylceramide synthase. Expert Opin Investig Drugs 2000;9:1787 - 96 
Heidler SA, Radding JA. The AUR1 gene in Saccharomyces cerevisiae encodes dominant 
resistance to the antifungal agent aureobasidin A (LY295337). Antimicrob Agents 
Chemother 1995;39:2765 - 69 
Heidler SA, Radding JA. Inositol phosphoryl transferases from human pathogenic fungi. 
Biochim Biophys Acta 2000;1500:147 - 52 
Hill AV. The possible effects of the aggregation of the molecules of huemoglobin on its 
dissociation curves. Proc Physiol Soc 1910 40(suppl):4 - 7 
Huitema K, van den Dikkenberg J, Brouwers JF, Holthuis JC. Identification of a family of 
animal sphingomyelin synthases. Embo J 2004;23:33 - 44  
International Union of Biochemistry. Units of enzyme activity. Eur J Biochem 1979;97:319 - 
20 
Leber A, Hrastnik C, Daum G. Phospholipid-synthesizing enzymes in Golgi membranes of 
the yeast, Saccharomyces cerevisiae. FEBS Lett 1995;377:271 - 274 
Lester RL, Dickson RC. Sphingolipids with inositolphosphate-containing head groups. Adv 
Lipid Res 1993;26: 253 - 74 
Levine TP, Wiggins CA, Munro S. Inositol phosphorylceramide synthase is located in the 
Golgi apparatus of Saccharomyces cerevisiae. Mol Biol Cell 2000;11:2267 - 81 
Magee T, Prinen N, Alder J, Pagakis SN, Parmryd I. Lipid rafts: cell surface platforms for 
T-cell signalling. Biol Res 2002;35:127 - 31 
Mina JG, Pan SY, Wansadhipathi NK, Bruce CR, Shams-Eldin H, Schwarz RT, Steel PG, 
Denny PW. The Trypanosoma brucei sphingolipid synthase, an essential enzyme and 
drug target. Mol Biochem Parasitol 2009;1688:16 - 23  
Nagiec MM, Nagiec EE, Baltisberger JA, Wells GB, Lester RL, Dickson RC. Sphingolipid 
synthesis as a target for antifungal drugs. J Biol Chem 1997;272:9809 - 17 
Nagiec MM, Nagiec EE, Baltisberger JA, Wells GB, Lester RL, Dickson RC. Sphingolipid 
synthesis as a target for antifungal drugs. Complementation of the inositol 
phosphorylceramide synthase defect in a mutant strain of Saccharomyces cerevisiae by 
the AUR1 gene. J Biol Chem 1997;272:9809 - 17 
Pierce SK. Lipid rafts and B-cell activation. Nature Rev Immunol 2002;2:96 - 105 
Remme JHF, Blas E, Chitsulo L, Desjeux PMP, Engers HD, Kanyok TP, Kengeya 
Kayondo JF, Kioy DW, Kumaraswami V, Lazdins JK, Nunn PP, Oduola A, Ridley R, Toure 
Y, Zicker F, Morel CMM. Strategic emphases for tropical diseases research: a TDR 
perspective. Trends Parasitol 2002;18:421 - 26 
 19 
Rouvinski A, Gahali-Sass I, Stav I, Metzer E, Atlan H, Taraboulos A. Both raft- and non-
raft proteins associate with CHAPS-insoluble complexes: some APP in large complexes. 
Biochem Biophys Res Commun 2003;308:750 - 58 
Schürholz T. Critical dependence of the solubilization of lipid vesicles by the detergent 
CHAPS on the lipid composition. Functional reconstitution of the nicotinic acetylcholine 
receptor into preformed vesicles above the critical micellization concentration. Biophysical 
Chemistry 1996;58:87 - 96 
Smith WL, Merrill AH. Sphingolipid metabolism and signaling. J Biol Chem 
2002;277:25841 - 42 
Sperling P, Heinz E. Plant sphingolipids: structural diversity, biosynthesis, first genes and 
functions. Biochim Biophys Acta 2003;1632:1 - 15 
Sutterwala SS, Hsu FF, Sevova ES, Schwartz KJ, Zhang K, Key P, Turk J, Beverley SM, 
Bangs JD. Developmentally regulated sphingolipid synthesisin African trypanosomes. Mol 
Microbiol 2008;70:281 - 96 
Suzuki E, Tanaka AK, Toledo MS, Levery SB, Straus AH, Takahashi HK. Trypanosomatid 
and fungal glycolipids and sphingolipids as infectivity factors and potential targets for 
development of new therapeutic strategies. Biochim Biophys Acta 2008;1780:362 - 69 
Tanaka, AK, Valero, VB, Takahashi, HK, Straus, AH. Inhibition of Leishmania 
(Leishmania) amazonensis growth and infectivity by aureobasidin A. J Antimicrob 
Chemother 2008;59:487 - 92 
Wu WI, Lin YP, Wang E, Merrill AH, Jr., Carman GM. Regulation of phosphatidate 
phosphatase activity from the yeast Saccharomyces cerevisiae by sphingoid bases. J Biol 
Chem 1993;268:13830 - 37 
Zhang J-H, Chung TDY, Oldenburg KR. A simple statistical parameter for use in 
evalutation and validation of high throughput screening assays. J Biomol Screening 
1999;4:67 - 73 
Zhang K, Hsu F-F, Scott DA, Docampo R, Turk J, Beverley SM. Leishmania salvage and 
remodelling of host sphingolipids in amastigote survival and acidocalcisome biogenesis. 
Mol Microbiol 2005;55:1566 – 78 
Zhang O, Wilson MC, Xu W, Hsu FF, Turk J, Kuhlmann FM, Wang Y, Soong L, Key P, 
Beverley SM, Zhang K. Degradation of host sphingomyelin is essential for Leishmania 
virulence. PLoS Pathog 2009;5:e1000692 
 
Figure legends 
 
 20 
Figure 1 Separation of NBD-C6-IPC product from NBD-C6-ceramide substrate by 
anion exchange chromatography 
Thin layer chromatography analysis of fractions demonstrating the separation of NBD-C6-
IPC product from NBD-C6-ceramide substrate. 
1 Reaction product; 2 Column flow through; 3 - 5 Methanol wash; 6 - 9 Elution 
Cer - NBD-C6-ceramide; IPC - NBD-C6-IPC 
 
Figure 2 Turnover of LmjIPCS in CHAPS-washed and crude (unwashed) microsomal 
preparations.  
Measured by the incorporation of the fluorescent acceptor substrate, NBD-C6-ceramide, 
into NBD-C6-IPC product. Fluorescent IPC was quantified following fractionation by 
HPTLC as described.  
A Assay of LmjIPCS activity in crude or washed microsomes with (black) or without 
(grey) the addition of the donor substrate, bovine phosphatidylinositol (PI). The 
background due to endogenous PI (grey) is reduced after washing the membraneous 
material. Results normalized with respect to +PI samples. 
B The specific activity of LmjIPCS, as determined by the formation of IPC, is enhanced 
in the washed microsomes. Note 2-fold increase in specific activity (based on total 
protein content per assay). 
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Figure 3 LmjIPCS turnover versus time, enzyme concentration and in presence of 
DAG  
Determined using the 96-well plate formatted assay as described, with fluorescent NBD-
C6-ceramide as acceptor substrate (5 µM), and bovine phosphatidylinositol (PI; 100 µM) 
as the donor substrate. IPC quantified with respect to NBD-C6-ceramide standard curve. 
All points in triplicate, error bars shown.  
A LmjIPCS turnover versus time. Turnover defined as pmol IPC produced per unit of 
enzyme (pmol.U−1) under the conditions employed. R² = 0.95  
B LmjIPCS turnover versus DAG concentration. Turnover is defined as pmol IPC 
produced per minute (pmol.min−1.U−1) under the conditions employed. R² = 0.86 
C LmjIPCS turnover versus enzyme concentration: linear range. Turnover is defined as 
pmol IPC produced per minute (pmol.min−1) under the conditions employed. R² = 
0.98 
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Figure 4 LmjIPCS turnover versus acceptor substrate (NBD-C6-ceramide) and donor 
substrate (phosphatidylinositol) concentrations 
Determined using the 96-well plate formatted assay as described, with fluorescent NBD-
C6-ceramide as acceptor substrate, and bovine phosphatidylinositol (PI) as the donor 
substrate. IPC quantified with respect to NBD-C6-ceramide standard curve. All points in 
triplicate, error bars shown.  
A LmjIPCS turnover (defined as pmol IPC.min−1.U−1; v0) demonstrated apparent 
Michaelis-Menton kinetics - vo = Vmax [S] / (Km + [S]) - with respect to the acceptor 
substrate NBD-C6-ceramide (S). Non-linear analysis calculated the apparent Km = 
3.5±0.35 µM; and the apparent Vmax = 2.1±0.1 pmol.min-1.U-1. R² = 0.97, indicating a 
good fit to the model. [PI] = 100 µM. 
B LmjIPCS turnover (vo ) with respect to the donor substrate (S), phosphatidylinositol 
(PI), did not fit the Michaelis-Menten model. R² = 0.76. [NBD-C6-ceramide] = 5 µM.  
C However, LmjIPCS turnover (vo ) with respect to PI fits a Michaelis-Menten model at 
high NBD-C6-ceramide concentration. R² = 0.93. Non-linear analysis calculated the 
apparent Km = 22.8±4.6µM and the apparent Vmax 2.0±0.07 pmol.min−1.U−1. [NBD-C6-
ceramide] = 20 µM. 
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Figure 5 LmjIPCS turnover with varying acceptor substrate (NBD-C6-ceramide) and 
different fixed donor substrate (phosphatidylinositol) concentrations 
Determined using the 96-well plate formatted assay as described, with fluorescent NBD-
C6-ceramide as acceptor substrate, and bovine phosphatidylinositol (PI) as the donor 
substrate. IPC quantified with respect to NBD-C6-ceramide standard curve. All points in 
triplicate, error bars shown as indicated. Donor (PI) and acceptor (ceramide) substrate 
concentrations varied as indicated. 
A Plots of 1 / v0 vs. 1 / [S]%, where S is NBD-C6-ceramide as a molar fraction. Initial 
velocities (v0) were determined with six concentrations of PI (12.5, 25, 37.5, 87.5 and 
100 µM). The data points were generated from three independent determinations of 
v0. Error bars were omitted for clarity. 
B Plot of the intercepts of 1 / v0 from A against 1 / [S]%, where S is PI as a molar 
fraction. 
C Simulation and experimental data 
[NBD-C6-ceramide] = variable, [PI] = 100 µM. 
D Simulation and experimental data 
[NBD-C6-ceramide] = 20 µM, [PI] = variable. 
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Figure 6 Competitive inhibition of LmjIPCS activity 
Determined using the 96-well plate formatted assay as described, with fluorescent NBD-
C6-ceramide as acceptor substrate, and bovine phosphatidylinositol (PI) as the donor 
substrate. IPC quantified with respect to NBD-C6-ceramide standard curve. All points in 
triplicate, error bars shown. Donor substrate (PI) concentration at 100 µM, acceptor (NBD-
C6-ceramide) substrate at 5 µM. 
logIC50 = log(10logKi(1+[NBD-C6-Cer] / NBD-C6-Cer Km)) 
[NBD-C6-Cer] = 5.0 µM, Km = 3.5 µM 
A  N-acetylsphingosine is a competitive inhibitor of LmjIPCS: logIC50 = 1.2±0.2; IC50 = 
16 µM; R² =0.83 
B  D-erythro-sphingosine is a competitive inhibitor of LmjIPCS: logIC50= 1.7±0.2; IC50 = 
53 µM; R² = 0.93 
 
Figure 7 Mass spectrometric analyses of reaction products from N-acetyl-D-erythro-
sphingosine 
Negative ion mass spectrum demonstrating that N-acetyl-D-erythro-sphingosine (AcSph, 
mass = 340.3) is a substrate for LmjIPCS, giving the product inositol phosphoryl acetyl-D-
erythro-sphingosine (IP-AcSph, mass = 582.3).  
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Supplementary data  
S1 Derivation of Equation 3  
The hypothetical catalytic reaction scheme assuming double displacement kinetics and 
initial rate conditions. 
ED: LmjIPCS associated with the detergent, CHAPS; PI: Phosphatidylinositol; ED.PI: 
LmjIPCS-PI complex; DAG: Diacylglycerol; ED.IP: Phosphorylated intermediate LmjIPCS 
with phosphorylinositol group; Cer: Ceramide; ED.IP.Cer: LmjIPCS-IP-Ceramide complex; 
ED.IPC: LmjIPCS-IPC complex; IPC: Inositol phosphorylceramide.  
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Table 1 
 
 
L. major 
promastigotes 
L. mexicana 
promastigotes 
L. mexicana 
amastigotes 
Miltefosine    
logLD50  0.20 0.15 1.10 
SE logLD50 0.06 0.06 0.03 
LD50 µM 1.59 1.41 12.6 
Sphingosine    
logLD50  0.81 0.91 1.12 
SE logLD50 0.13 0.14 0.04 
LD50 µM 6.49 8.18 13.3 
Acetylceramide    
logLD50  1.63 1.81 ND 
SE logLD50 0.14 0.18 ND 
LD50 µM 43.0 64.5 ND 
 
ND = not determined; LD50 = lethal dose, 50%; SE = standard error 
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